These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7719116)

  • 1. Determination of epidermal proliferative activity in experimental mouse tail test by AgNOR analysis.
    Heinisch G; Wozel G
    Exp Toxicol Pathol; 1995 Jan; 47(1):19-23. PubMed ID: 7719116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
    Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
    Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nucleolus organizer regions in pathomorphologic tumor diagnosis].
    Rüschoff J
    Veroff Pathol; 1992; 139():1-144. PubMed ID: 1413987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of the AgNOR method for the differential diagnosis of tumors and for the quantification of non-neoplastic epidermal hyperproliferation in dermatohistology].
    Heinisch G; Barth J
    Zentralbl Pathol; 1994 Mar; 140(1):95-101. PubMed ID: 7515680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified silver staining of nucleolar organizer regions to improve the accuracy of image analysis.
    Orrea SC; Tomasi VH; Schwint AE; Itoiz ME
    Biotech Histochem; 2001 Mar; 76(2):67-73. PubMed ID: 11440307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An improved system for quantifying AgNOR and PCNA in canine tumors.
    Hung LC; Pong VF; Cheng CR; Wong FI; Chu RM
    Anticancer Res; 2000; 20(5A):3273-80. PubMed ID: 11062753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AgNOR content and PCNA expression in transplanted malignant neurinoma in rats.
    Mennel HD; Rickert D
    Pathol Res Pract; 1994 May; 190(5):423-8. PubMed ID: 7991463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of proliferative activity by AgNOR and PCNA in prostatic tissues of ram lambs implanted with zeranol.
    Gulbahar MY; Yuksel H; Guvenc T; Okut H
    Reprod Domest Anim; 2005 Oct; 40(5):468-74. PubMed ID: 16149954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in the occurrence of silver-staining nucleolar organizer regions (AgNORs) in non-proliferating and proliferating tissues.
    Leek RD; Alison MR; Sarraf CE
    J Pathol; 1991 Sep; 165(1):43-51. PubMed ID: 1955934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of proliferating cell nuclear antigen and nucleolar organizer region in testicular tumors].
    Kurisu H; Shimabukuro T; Wada T; Yamamoto M; Shameem IA; Otsuka T; Sakano S; Matsuyama H; Naito K; Yamamoto N
    Hinyokika Kiyo; 1993 Aug; 39(8):715-20. PubMed ID: 8104387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of proliferative activity in Wilms' tumour.
    Delahunt B; Farrant GJ; Bethwaite PB; Nacey JN; Lewis ME
    Anal Cell Pathol; 1994 Aug; 7(2):127-38. PubMed ID: 7993823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleolar organizer regions in human esophageal disorders: comparison with proliferating cell nuclear antigen by immunostaining.
    Miyazaki S; Sasano H; Suzuki T; Sawai T; Nishihira T; Mori S
    Mod Pathol; 1992 Jul; 5(4):396-401. PubMed ID: 1353881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Significance of the AgNOR in tumor pathology].
    Pich A; Margaria E; Chiusa L
    Pathologica; 2002 Feb; 94(1):2-9. PubMed ID: 11912874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [AgNOR analysis of astrocytoma in childhood].
    Haberland C; Martin H; Guski H; Hufnagl P; Vogel S
    Zentralbl Neurochir; 1996; 57(1):5-11. PubMed ID: 8900893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Silver-stained Nucleolar Organizer Regions (AgNOR)].
    Derenzini M; Trerè D
    Pathologica; 2001 Apr; 93(2):99-105. PubMed ID: 11428299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [AgNOR expression in skin tumors. Studies of melanocytic, epidermal and fibrohistiocytic lesions].
    Heinisch G; Barth J
    Hautarzt; 1995 Mar; 46(3):177-85. PubMed ID: 7759244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Argyrophilic nuclear organizer regions in nasopharyngeal carcinoma and paraneoplastic epithelia.
    Chen M; Lee JC; Lo S; Shen J
    Head Neck; 2003 May; 25(5):395-9. PubMed ID: 12692877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours.
    Yu CC; Fletcher CD; Newman PL; Goodlad JR; Burton JC; Levison DA
    J Pathol; 1992 Feb; 166(2):147-52. PubMed ID: 1348532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic role of proliferation activity in human CNS tumours: the determination of AgNOR, PCNA and Ki-67 expression. Part 1: AgNOR expression in CNS tumours.
    Janczukowicz J
    Folia Neuropathol; 2003; 41(2):97-101. PubMed ID: 12899202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.